Enrolled patients
HNSCCs at stage III-IV, oropharyngeal carcinoma, squamous cell carcinomas, allergies, Cancer
METASTASIS, SQUAMOUS CELL CARCINOMAS, ALLERGIES, CANCER
This was a prospective, single-arm, single-centre clinical trial (registration no.: ChiCTR2200055719). Patients recently treated for HNSCCs at the National Cancer Centre/Cancer Hospital of the Chinese Academy of Medical Sciences between April 2021 and June 2022 were enrolled. The inclusion criteria were aged ≥18 y with histopathologically confirmed squamous cell carcinomas and locally advanced cases of P16-positive oropharyngeal carcinoma at clinical stage II-III, or non-P16-positive oropharyngeal carcinoma and other HNSCCs at stage III-IV suitable for complete surgical resection. The exclusion criteria were previous treatment with PD-1 monoclonal antibodies or similar drugs, radical surgical resection not possible, distant metastasis and allergies to the drugs used in this study. The study protocol was approved by the Ethics Committee of the National Cancer Centre/Cancer Hospital of the Chinese Academy of Medical Sciences (approval no.: 21/056-2727). All enrolled patients gave written informed consent to trial participation.